Universal antiretroviral therapy for HIV-infected children: A review of the benefits and risks to consider during implementation: A

Journal of the International AIDS Society

Volumn 20, Issue 1, 2017, Pages

  Barlow Mosha, Linda ^a   Musiime, Victor ^a,b   Davies, Mary Ann ^c   Prendergast, Andrew J ^d,e,f   Musoke, Philippa ^a   Siberry, George ^g   Penazzato, Martina ^h  

^a MAKERERE UNIVERSITY   (Uganda)

^b JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e Zvitambo Institute for Maternal and Child Health Research   (Zimbabwe)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

adolescents; children; resource limited settings; review; Sub Saharan Africa; Universal antiretroviral therapy; WHO guidelines

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIRETROVIRAL THERAPY; CASE CONTROL STUDY; CHILD; CHILD GROWTH; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DEATH; DISEASE BURDEN; DRUG SAFETY; FOLLOW UP; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION; IMMUNE SYSTEM; NERVE CELL DIFFERENTIATION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; VIRUS RESISTANCE; WORLD HEALTH ORGANIZATION; ADOLESCENT; MALE; RISK ASSESSMENT;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; HIV INFECTIONS; HUMANS; MALE; RISK ASSESSMENT;

EID: 85037587443     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.20.1.21552     Document Type: Review

References (66)

1. UNAIDS. 2016 Global plan progress report. [cited Jul 2016 22]. Available from: http://www.unaids.org/en/resources/documents/2016/GlobalPlan2016
2. WHO. Health for the world adolescents. [cited 2015 Sept 29]. Available from: http://apps.who.int/adolescent/second-decade/
3. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F,. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004; 364: 1236-43.
4. Ferrand RA, Corbett EL, Wood R, Hargrove J, Ndhlovu CE, Cowan FM, et al., AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS. 2009; 23: 2039-46.
5. Gray GE,. Adolescent HIV-cause for concern in Southern Africa. PLoS Med. 2010 Feb 2; 7 (2): e1000227.
6. Vreeman RC, Scanlon ML, McHenry MS, Nyandiko WM,. The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children. J Int AIDS Soc. 2015 Dec 2;18(Suppl 6): 20258.
7. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva, Switzerland: WHO; 2016.
8. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al., Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008; 359: 2233-44.
9. Puthanakit T, Saphonn V, Ananworanich J, Kosalaraksa P, Hansudewechakul R, Vibol U, et al., Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis. 2012 Dec; 12 (12): 933-41.
10. Schomaker M, Leroy V, Wolfs T, Technau KG, Renner L, Judd A, et al., Optimal timing of antiretroviral treatment initiation in HIV positive children and adolescents-A multiregional analysis from Southern Africa, West Africa and Europe. Int J Epidemiol. 2016 Jun 24. [Epub ahead of print].
11. Schomaker M, Egger M, Ndirangu J, Phiri S, Moultrie H, Technau K, et al., When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa. PLoS Med. 2013 Nov; 10 (11): e1001555.
12. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al., Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015 Aug 27; 373 (9): 795-807.
13. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al., A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015 Aug 27; 373 (9): 808-22.
14. Peacock-Villada E, Richardson BA, John-Stewart GC,. Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries. Pediatrics. 2011 Feb; 127 (2): e423-41.
15. Berhane R, Bagenda D, Marum L, Aceng E, Ndugwa C, Bosch RJ, et al., Growth failure as a prognostic indicator of mortality in pediatric HIV infection. Pediatrics. 1997; 100 (1): E7.
16. Chantry CJ, Byrd RS, Englund JA, Baker CJ, McKinney RE Jr,. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. Pediatr Infect Dis J. 2003; 22: 1033-39.
17. Musoke PM, Mudiope P, Barlow-Mosha LN, Ajuna P, Bagenda D, Mubiru MM, et al., Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study. BMC Pediatr. 2010 Aug; 6 (10): 56.
18. Arpadi SM, Cuff PA, Kotler DP, Wang J, Bamji M, Lange M, et al., Growth velocity, fat-free mass and energy intake are inversely related to viral load in HIV-infected children. J Nutr. 2000; 130: 2498-502.
19. McGrath CJ, Chung MH, Richardson BA, Benki-Nugent S, Warui D, John-Stewart GC,. Younger age at HAART initiation is associated with more rapid growth reconstitution. AIDS. 2011 Jan 28; 25 (3): 345-55.
20. Szubert AJ, Musiime V, Bwakura-Dangarembizi M, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, et al., Pubertal development in HIV-infected African children on first-line antiretroviral therapy. AIDS. 2015 Mar 13; 29 (5): 609-18.
21. Jesson J, Koumakpai S, Diagne NR, Amorissani-Folquet M, Koueta F, Aka A, et al., Effect of age at antiretroviral therapy initiation on catch-up growth within the first 24 months among HIV-infected children in the IeDEA West African pediatric cohort. Pediatr Infect Dis J. 2015 Jul; 34 (7): e159-68.
22. Williams PL, Abzug MJ, Jacobson DL, Wang J, van Dyke RB, Hazra R, et al., Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment. AIDS. 2013 Jul 31; 27 (12): 1959-70.
23. Kekitiinwa A, Lee KJ, Walker AS, Maganda A, Doerholt K, Kitaka SB, et al., Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the UK/Ireland. J Acquir Immune Defic Syndr. 2008; 49: 384-92.
24. Puthanakit T, Kerr S, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V,. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J. 2009; 28: 488-92.
25. Picat MQ, Lewis J, Musiime V, Prendergast A, Nathoo K, Kekitiinwa A, et al., Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study. PLoS Med. 2013 Oct; 10 (10): e1001542.
26. Desmonde S, Dicko F, Koueta F, Eboua T, Balestre E, Amani-Bosse C, et al., Association between age at antiretroviral therapy initiation and 24-month immune response in West-African HIV-infected children. AIDS. 2014 Jul 17;28 (11): 1645-55.
27. Pierson T, McArthur J, Siliciano RF,. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol. 2000; 18: 665-708.
28. Ananworanich J, Puthanakit T, Suntarattiwong P, Chokephaibulkit K, Kerr SJ, Fromentin R, et al., Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS. 2014 Apr 24; 28 (7): 1015-20.
29. Le Doare K, Bland R, Newell ML,. Neurodevelopment in children born to HIV-infected mothers by infection and treatment status. Pediatrics. 2012 Nov; 130 (5): e1326-44.
30. Brahmbhatt H, Boivin M, Ssempijja V, Kigozi G, Kagaayi J, Serwadda D, et al., Neurodevelopmental benefits of antiretroviral therapy in Ugandan children aged 0-6 years with HIV. J Acquir Immune Defic Syndr. 2014 Nov 1; 67 (3): 316-22.
31. Laughton B, Cornell M, Boivin M, van Rie A,. Neurodevelopment in perinatally HIV-infected children: a concern for adolescence. J Int AIDS Soc. 2013 Jun; 18 (16): 18603.
32. Dangor Z, Izu A, Hillier K, Solomon F, Beylis N, Moore DP, et al., Impact of the antiretroviral treatment program on the burden of hospitalization for culture-confirmed tuberculosis in South African children: a time-series analysis. Pediatr Infect Dis J. 2013 Sep; 32 (9): 972-77.
33. Brown SC, Schoeman CJ, Bester CJ,. Cardiac findings in children admitted to a hospital general ward in South Africa: a comparison of HIV-infected and uninfected children. Cardiovasc J S Afr. 2005; 16: 206-10.
34. Lubega S, Zirembuzi GW, Lwabi P,. Heart disease among children with HIV/AIDS attending the paediatric infectious disease clinic at Mulago Hospital. Afr Health Sci. 2005; 5: 219-26.
35. Okoromah CA, Ojo OO, Ogunkunle OO,. Cardiovascular dysfunction in HIV-infected children in a sub-Saharan African country: comparative cross-sectional observational study. J Trop Pediatr. 2012 Feb; 58 (1): 3-11.
36. Lipshultz SE, Williams PL, Wilkinson JD, Leister EC, van Dyke RB, Shearer WT, et al., Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study. JAMA Pediatr. 2013 Jun; 167 (6): 520-27.
37. Jeena PM, Coovadia HM, Thula SA, Blythe D, Buckels NJ, Chetty R,. Persistent and chronic lung disease in HIV-1 infected and uninfected African children. AIDS. 1998; 12: 1185-93.
38. Lowenthal ED, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand RA,. Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. Lancet Infect Dis. 2014 Jul; 14 (7): 627-39.
39. Weber HC, Gie RP, Cotton MF,. The challenge of chronic lung disease in HIV-infected children and adolescents. J Int AIDS Soc. 2013 Jun; 18 (16): 18633.
40. Ferrand RA, Desai SR, Hopkins C, Elston CM, Copley SJ, Nathoo K, et al., Chronic lung disease in adolescents with delayed diagnosis of vertically acquired HIV infection. Clin Infect Dis. 2012 Jul; 55 (1): 145-52.
41. Masekela R, Anderson R, Moodley T, Kitchin OP, Risenga SM, Becker PJ, et al., HIV-related bronchiectasis in children: an emerging spectre in high tuberculosis burden areas. Int J Tuberc Lung Dis. 2012 Jan; 16 (1): 114-19.
42. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: WHO; 2013.
43. Chan AK, Ford D, Namata H, Muzambi M, Nkhata MJ, Abongomera G, et al., The lablite project: a cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe. BMC Health Serv Res. 2014; 19 (14): 352.
44. Ministry-of-Health-Uganda. Addendum to national antiretroviral guidelines. Kampala, Uganda: Ministry-of-Health-Uganda; 2014.
45. WHO. Programmatic update; Maximizing the treatment and prevention potential of antiretroviral drugs: early country experiences towards implementing a treat-all policy. Geneva, Switzerland: WHO; 2015.
46. Elyanu P, Narayan, V, Grosz J, McConnel I, Kondabolu P, Namagala E,. Critical gaps and reasons for delayed ART initiation and poor retention of HIV positive children in Uganda. XIX International AIDS Conference; 2012 July 22-27. Washington DC, USA.
47. Teasdale CA, Apicella L, M L, Thome B, Yersin I, Ahoua L, et al., Determinants of retention and mortality among HIV infected children at ICAP-supported care and treatment facilities in Mozambique(2004-2011). 5th International workshop on HIV Pediatrics; 2013 Jun 28-29; Kualar Lumpur, Malaysia.
48. Fortuny C, Deya-Martinez A, Chiappini E, Galli L, de Martino M, Noguera-Julian A,. Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents. Pediatr Infect Dis J. 2015 May;34(5 Suppl 1): S36-43.
49. Leeansyah E, Cameron PU, Solomon A, Tennakoon S, Velayudham P, Gouillou M, et al., Inhibition of telomerase activity by human iimunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr; 207 (7): 1157-65.
50. Tukei VJ, Asiimwe A, Maganda A, Atugonza R, Sebuliba I, Bakeera-Kitaka S, et al., Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. J Acquir Immune Defic Syndr. 2012 Mar 1; 59 (3): 274-80.
51. Wintergerst U, Hoffmann F, Jansson A, Notheis G, Huss K, Kurowski M, et al., Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother. 2008; 61: 1336-39.
52. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G,. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007; 146: 564-73.
53. Blazquez D, Ramos-Amador JT, Sainz T, Mellado MJ, Garcia-Ascaso M, De Jose MI, et al., Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. BMC Infect Dis. 2015 Mar; 8 (15): 119.
54. Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, et al., Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. Pediatr Infect Dis J. 2015 Feb; 34 (2): e23-31.
55. Dejkhamron P, Unachak K, Aurpibul L, Sirisanthana V,. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy. J Pediatr Endocrinol Metab. 2014 May;27(5-6): 403-12.
56. Kinabo GD, Sprengers M, Msuya LJ, Shayo AM, van Asten H, Dolmans WM, et al., Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy. Pediatr Infect Dis J. 2013 Jan; 32 (1): 39-44.
57. Piloya T, Bakeera-Kitaka S, Kekitiinwa A, Kamya MR,. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. J Int AIDS Soc. 2012 Jul 2; 15 (2): 17427.
58. Warszawski J, Lechenadec J, Faye A, Dollfus C, Firtion G, Meyer L, et al., Long-term nonprogression of HIV infection in children: evaluation of the ANRS prospective French pediatric cohort. Clin Infect Dis. 2007; 45: 785-94.
59. Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL,. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2012 Oct; 56 (10): 5000-08.
60. Gupta RK, Ford D, Mulenga V, Walker AS, Kabamba D, Kalumbi M, et al., Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine. Pediatr Infect Dis J. 2010 Aug; 29 (8): e57-62.
61. Musiime V, Kaudha E, Kayiwa J, Mirembe G, Odera M, Kizito H, et al., Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children. AIDS Res Hum Retroviruses. 2013 Mar; 29 (3): 449-55.
62. Sigaloff KC, Kayiwa J, Musiime V, Calis JC, Kaudha E, Mukuye A, et al., Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line anti-retroviral therapy. AIDS Res Hum Retroviruses. 2013 Jun; 29 (6): 925-30.
63. Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, et al., Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet. 2011 May 7; 377 (9777): 1580-87.
64. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al., Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009; 51: 65-71.
65. Bakeera-Kitaka S, Nabukeera-Barungi N, Nostlinger C, Addy K, Colebunders R,. Sexual risk reduction needs of adolescents living with HIV in a clinical care setting. AIDS Care. 2008; 20: 426-33.
66. Musiime V, Kayiwa J, Kiconco M, Tamale W, Alima H, Mugerwa H, et al., Response to antiretroviral therapy of HIV type 1-infected children in urban and rural settings of Uganda. AIDS Res Hum Retroviruses. 2012 Dec; 28 (12): 1647-57.